Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 4/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 4/20 | 0.47 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 14/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 13/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394245 | 1.00 | STIM1 (0.47) | STIM1ORAI1ORAI2FEN1ALOX5AP | |
| SCHEMBL1701172 | 0.84 | ALOX5AP (0.38) | STIM1ORAI1ORAI2FEN1ALOX5AP | |
| SCHEMBL12156317 | 0.82 | STIM1 (0.47) | STIM1ORAI1ORAI2 | |
| SCHEMBL1702358 | 0.82 | STIM1 (0.55) | STIM1ORAI1ORAI2FEN1ALOX5AP | |
| SCHEMBL12156322 | 0.80 | STIM1 (0.56) | STIM1ORAI1ORAI2 | |
| SCHEMBL1701752 | 0.78 | STIM1 (0.56) | STIM1ORAI1ORAI2FEN1 | |
| SCHEMBL12241542 | 0.75 | STIM1 (0.62) | STIM1ORAI1ORAI2 | |
| SCHEMBL12155542 | 0.73 | STIM1 (0.60) | STIM1ORAI1ORAI2 | |
| SCHEMBL22636402 | 0.72 | STIM1 (0.52) | STIM1ORAI1ORAI2 | |
| SCHEMBL29393757 | 0.72 | STIM1 (0.52) | STIM1ORAI1ORAI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905248-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| WO-2022101654-A1 | IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORS | CALCIMEDICA, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3965760-A1 | SYNTHESIS OF CRAC CHANNEL INHIBITORS | Calcimedica, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220056053-A1 | SYNTHESIS OF CRAC CHANNEL INHIBITORS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2022-02-24 | — | — | US | disclosed |
| CN-114072143-A | Synthesis of CRAC channel inhibitors | 钙医学公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2020227312-A1 | SYNTHESIS OF CRAC CHANNEL INHIBITORS | CALCIMEDICA, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227312-A1 | SYNTHESIS OF CRAC CHANNEL INHIBITORS | CALCIMEDICA, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20130345240-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8546403-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2013059677-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059677-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| EP-2563776-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
| US-20220056053-A1 | SYNTHESIS OF CRAC CHANNEL INHIBITORS | CACNA1E, CACNA1C, ORAI1 | STIM1 53/4885ORAI1 3/4885ORAI2 13/4885 |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
| US-11905248-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
| US-20130345240-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.